DelveInsight Business Research LLP

Albany, NY -- (SBWire) -- 09/13/2018 --Neuroendocrine tumors (NETs) consists of complex group of tumors that develop predominantly in the digestive or respiratory tracts, but can occur in many areas of the body. These tumors arise from cells called neuroendocrine cells. Like all cancers, NETs develop when the specialized cells undergo changes causing them to divide uncontrollably and grow into an abnormal tissue mass (tumor)". Neuroendocrine tumors are classified based on different criteria as- Anatomic site of origin, symptoms, malignancy, grade and stage. NETs is more predominant in males as compared to females.

According to the report of DelveInsight "Neuroendocrine Tumors (NETs) Market Insights, Epidemiology and Market Forecast-2027" the total prevalent population of NETs in 7 major markets were XXXX and total incident cases were XXXX in 2016. DelveInsight also estimates higher prevalent cases of NETs in the United States with XXXX prevalent cases in 2016, followed by EU5 and Japan. Among the EU5 countries, Germany has the highest prevalent population of NETs with XXXX cases, followed by the France. Spain has the lowest prevalent cases. Approximately XX% of NETs patients are functional, and XX% cases non-functional. In 2016, there were XXXX functional and XXXX non-functional cases of NETs in the United States. DelveInsight's analysts have assessed that approximately XX% of NETs patients have tumor at GEP sites, XX% at lung sites and XX% at other sites in the United States.

Market Outlook

Market analysis study carried out for the period of 2016-2027 demonstrates that the Market size of Neuroendocrine tumors (NETs) was about USD XXXX billion in 2016 in 7MM. The treatment starts with surgery being as the curative option for NETs. Medication are often considered after surgery. Cytotoxic therapies considered in the palliation of patients with advanced pancreatic NETs and symptoms related to tumor bulk. However, for the distant tumors that have grown outside, where regional therapies don't work, systemic therapies are the options for treatment. United States has the highest market share of NETs in 2016, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among EU5, Germany has the highest market, while Spain had the lowest market in 2016.

Emerging Drugs Analysis

There are several therapies available for the treatment of NETs, associated adverse events; high cost; restricted use of targeted therapy and unsatisfactory efficacy has emerged the need of more potential targeted therapy. Although there are numerous drugs in different phases of clinical trials claiming a better future treatment of NETs; only XX drugs are expected to enter the NETs market by 2027. The dynamics of Neuroendocrine Tumors (NETs) market is anticipated to change in the coming years owing to the expected launch of potential therapies.

The report covers a descriptive overview of the Neuroendocrine Tumors (NETs), explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Neuroendocrine Tumors (NETs) and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Neuroendocrine Tumors (NETs) are provided, along with assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Neuroendocrine Tumors (NETs) market is included in the report, covering drug outreach in 7MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Neuroendocrine Tumors (NETs) market.

Request for sample pages

Reasons to buy:

1. The report will help in developing business strategies by understanding trends shaping and driving the
Neuroendocrine Tumors market.
2. To understand the future market competition in the Neuroendocrine Tumors market and Insight reviews of the key market drivers and barriers.
3. Identification of strong upcoming players in the Neuroendocrine Tumors market will help in devising strategies that will help in getting ahead of competitors.
4. In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.

Companies Covered:

1. Progenics Pharmaceuticals
2. Hutchison MediPharma
3. Pfizer
And many others……………

Table of contents

1. Key Insights
2. Neuroendocrine Tumors Epidemiology Overview at a Glance
3. Disease Background and Overview: Neuroendocrine Tumors (NETs)
4. Epidemiology and Patient Population
5. Treatment Algorithm
6. Unmet needs
7. Marketed drugs
7.1. Drug 1: Company 1
7.2. Drug 2: Company 2
7.3. Drug 3: Company 3
8. Emerging drugs
9. Key Cross Competition
9.1. Drug 1: Novartis
9.2. Drug 2: Merck
9.3. Drug 3: Company 3
9.4. Drug 4: Company 4
9.5. Drug 5: Company 5
9.6. Drug 6: Company 6
9.7. Drug 7: Company 7
9.8. Drug 8: Company 8
9.9. Drug 9: Company 9
9.10. Drug 10: Company 10
9.11. Drug 11: Company 11
9.12. Drug 12: Company 12
9.13. Drug 13: Company 13
9.14. Drug 14: Company 14
9.15. Drug 15: Company 15
9.16. Drug 16: Company 16
9.17. Drug 17: Company 17
9.18. Drug 18: Company 18
9.19. Drug 19: Company 19
9.20. Drug 20: Company 20
9.21. Drug 21: Company 21
9.22. Drug 22: Company 22
9.23. Drug 23: Company 23
9.24. Drug 24: Company 24
9.25. Drug 25: Company 25
9.26. Drug 26: Company 26
9.27. Drug 27: Company 27
10. Neuroendocrine Tumors: 7 Major Market Analysis
10.1. Key Findings
10.2. Market Size of Neuroendocrine Tumors (NETs) in 7MM
10.3. Market Outlook by Country
10.4. The United States: Market Outlook
10.5. EU-5 Countries: Market Outlook
10.6. Germany
10.7. France
10.8. United Kingdom
10.9. Spain
10.10. Italy
10.11. Japan
11. Market Drivers
12. Market Barriers
13. Appendix
14. DelveInsight Capabilities
15. Disclaimer

*** For detailed TOC request for sample pages.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses

We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.